Research programme: anti-transforming growth factor beta antibodies- XOMA Corporation/Novartis

Drug Profile

Research programme: anti-transforming growth factor beta antibodies- XOMA Corporation/Novartis

Alternative Names: XOMA-089

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XOMA
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Transforming growth factor beta1 inhibitors; Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Fibrosis

Highest Development Phases

  • Preclinical Cancer; Fibrosis

Most Recent Events

  • 16 Mar 2017 Xoma has patent protection for anti-TGFβ antibody programme in USA
  • 01 Oct 2015 XOMA Corporation's anti-transforming growth factor beta antibody program licensed to Novartis worldwide
  • 06 Aug 2015 Interim pharmacodynamics data from a preclinical trial in fibrosis released by XOMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top